We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease
Authors
Pfister, Edith L.Dinardo, Natalie
Mondo, Erica
Borel, Florie
Conroy, Faith
Gernoux, Gwladys
Kennington, Lori A.
Moser, Richard P.
Sena-Esteves, Miguel
Gao, Guangping
Mueller, Christian
Aronin, Neil
Student Authors
Erica MondoAcademic Program
NeuroscienceUMass Chan Affiliations
RNA Therapeutics InstituteDepartment of Pediatrics, Division of Pediatric Pulmonology
Horae Gene Therapy Center, Vector Core
Department of Neurology
Department of Neurosurgery
Horae Gene Therapy Center
Department of Medicine
Document Type
Journal ArticlePublication Date
2017-12-05
Metadata
Show full item recordAbstract
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT but evidence for their effectiveness and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT with 73 CAG repeats. We used AAV9 to unilaterally deliver to HD sheep striatum an artificial miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters- U6 or CbetaA. The treatment reduced human mutant (m) HTT mRNA and protein 50-80% in the striatum at one and six-months post-injection. Silencing was detectable in both caudate and putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant loss of neurons labeled by DARPP32 or NeuN at six months after treatment, Iba1-positive microglia were detected at control levels. We conclude that safe and effective silencing of human mHTT protein can be achieved and sustained in a large animal brain by direct delivery of an AAV carrying an artificial miRNA.Source
Hum Gene Ther. 2017 Dec 5. doi: 10.1089/hum.2017.199. Link to article on publisher's site
DOI
10.1089/hum.2017.199Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43626PubMed ID
29207890Notes
Full list of authors omitted for brevity. For full list see article.
Related Resources
ae974a485f413a2113503eed53cd6c53
10.1089/hum.2017.199